BioMarin Pharmaceutical Inc. buy UBS Group AG
Start price
20.02.25
/
50%
€65.70
Target price
20.02.26
€108.05
Performance (%)
-24.17%
Price
13.08.25
€49.82
Summary
This prediction is currently active. The price of BioMarin Pharmaceutical Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -24.17%. This prediction currently runs until 20.02.26. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| BioMarin Pharmaceutical Inc. | -4.266% | -4.266% |
| iShares Core DAX® | 1.043% | -0.149% |
| iShares Nasdaq 100 | 1.920% | 4.604% |
| iShares Nikkei 225® | 4.840% | 8.328% |
| iShares S&P 500 | 1.567% | 3.310% |
Comments by UBS_Group_AG for this prediction
In the thread BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $109.00 to $113.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
Stopped prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€51.06
05.08.25
05.08.25
€98.62
05.08.26
05.08.26
-2.43%
13.08.25
13.08.25
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€62.34
30.10.24
30.10.24
€97.65
30.10.25
30.10.25
-20.08%
13.08.25
13.08.25